Literature DB >> 10376950

Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis.

D R Huang1, R Pirskanen, G Matell, A K Lefvert.   

Abstract

The mechanism behind the association between MHC genes and myasthenia gravis (MG) is not fully understood. In the present study we studied the associations with polymorphisms at HLA-DR3, HLA-B8 and TNF-alpha genes in Swedish patients and healthy individuals. The TNF-alpha-308 allele 2 was associated with female patients having disease onset before the age 40 and with thymic hyperplasia. Analysis of strongest associations between MG and alleles close to TNF-alpha indicated that the association of TNF-alpha was possibly stronger than for HLA-DR3 and nearly the same as for HLA-B8. Peripheral blood mononuclear cells from patients positive for TNF-alpha -308 allele 2 had higher secretion of TNF-alpha when stimulated by anti-CD3 antibodies. Our results indicate that a subgroup of MG patients who have been previously shown to be associated with MHC genes may have a higher inducible TNF-alpha level in vivo, thus resulting the pathological changes in the thymus and the early onset of MG.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10376950     DOI: 10.1016/s0165-5728(98)00253-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

1.  Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia.

Authors:  Claire Vandiedonck; Geneviève Beaurain; Matthieu Giraud; Catherine Hue-Beauvais; Bruno Eymard; Christine Tranchant; Philippe Gajdos; Jean Dausset; Henri-Jean Garchon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

2.  Single-nucleotide polymorphisms in the B7H3 gene are not associated with human autoimmune myasthenia gravis.

Authors:  Priya Sakthivel; Xiongbiao Wang; Baback Gharizadeh; Ricardo Giscombe; Ritva Pirskanen; Pål Nyren; Ann Kari Lefvert
Journal:  J Genet       Date:  2006-12       Impact factor: 1.166

Review 3.  Precision medicine in myasthenia graves: begin from the data precision.

Authors:  Hai-Feng Li; Yu Hong; Yanchen Xie; Hong-Jun Hao; Ren-Cheng Sun
Journal:  Ann Transl Med       Date:  2016-03

4.  The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis.

Authors:  Amel Meraouna; Geraldine Cizeron-Clairac; Rozen Le Panse; Jacky Bismuth; Frederique Truffault; Chantal Tallaksen; Sonia Berrih-Aknin
Journal:  Blood       Date:  2006-03-16       Impact factor: 22.113

Review 5.  A cellular viewpoint of anti-FVIII immune response in hemophilia A.

Authors:  Sebastien André; Yann Meslier; Jordan D Dimitrov; Yohann Repessé; Srinivas V Kaveri; Sebastien Lacroix-Desmazes; Suryasarathi Dasgupta
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

6.  Human Leucocyte Antigen B50 Is Associated with Conversion to Generalized Myasthenia Gravis in Patients with Pure Ocular Onset.

Authors:  Bedile Irem Tiftikcioglu; Irem Fatma Uludag; Yasar Zorlu; İbrahim Pirim; Ufuk Sener; Figen Tokucoglu; Meltem Korucuk
Journal:  Med Princ Pract       Date:  2016-10-31       Impact factor: 1.927

7.  CCR2-64I and CCR5Delta32 Polymorphisms in Korean Patients with Myasthenia Gravis.

Authors:  Hyun Sook Kim; Dae-Seong Kim; Eun Young Lee; Il-Nam Sunwoo; Young-Chul Choi
Journal:  J Clin Neurol       Date:  2007-09-20       Impact factor: 3.077

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.